Speaker Bios

[This text is here for extra space]
Christopher Austin, National Center for Advancing Translational Sciences (NCATS), please follow link for bio.

François-Henri Boissel, a securitization banker and entrepreneur, is cofounder and CEO of Novadiscovery, a consulting company specialized in quantitative modeling & simulation applied to pharmaceutical R&D, incorporated in 2010. Novadiscovery has developed a unique framework to evaluate a drug asset based on the in-silico prediction of real-life clinical outcomes from the early phases of R&D. This technology enables drug companies to make better resources allocation decisions and establish a drug’s proof-of-commercial relevance upstream with a view to build a convincing value proposition for regulators and payers.

François-Henri started his professional career in 2004 with Lehman Brothers in London and subsequently Tokyo. In London, he helped launch the bank’s European non-performing loans (NPL) securitization operations. Acting in a principal capacity, he was involved in a variety of securitization deals, from whole business securitizations (nursing homes, telecom towers, etc.) to commercial and residential mortgages and consumer finance loans securitizations. In Asia, he closed the first residential NPL securitization deal in Malaysia. He was also heavily involved in the debt restructuring of the world’s largest Build-Operate-Transfer project in Taiwan, amounting to $13bl of refinancing to term out the OpCo’s liabilities and hedge its long-term inflation risk.

François-Henri earned an M.B.A. from ESSEC Business School (Paris).

Rena M. Conti, PhD, is an expert on the financing, regulation and organization of medical care, with an emphasis on the biopharmaceutical market and oncology practice. She is an Assistant Professor of Health Policy at the University of Chicago in the Department of Pediatrics, section of hematology/oncology, and the Department of Public Health Sciences where she teaches University-wide graduate level courses in the Economics and Regulation of the Biopharmaceutical Industry and Health Economics. Dr. Conti is a 2007 graduate of the Harvard University Interfaculty Initiative in health policy (economics concentration). She currently serves on the Government Affairs committee, the American Society of Clinical Oncology and is co-director of the economics working group for the Cancer Therapy Evaluation Program, National Cancer Institute.

Doug Criscitello leads Grant Thornton’s public sector financial institutions business unit and focuses on issues residing at the intersection of government and banking. Previously, Doug was chief financial officer at the Department of Housing & Urban Development, appointed by President Obama, where he directed the execution of HUD’s financial management program, including analytical work involving the department’s credit and insurance programs. Before HUD, his prior position in the public sector was as founding director of the New York City Independent Budget Office, a municipal government agency designed to provide nonpartisan, objective research and analysis of NYC’s budget. Prior to IBO, Doug spent a decade in the federal government focused on credit and insurance programs at both the Office of Management and Budget and at the Congressional Budget Office. Immediately prior to his appointment at HUD, he worked in JPMorgan’s Financial Institutions Group, where he provided operational, investment banking, and financial advisory services to U.S. government agencies and related entities along with multilateral development banks based in Washington DC.

Doug Dachille, First Principles Capital Management, please follow link for bio.

Duncan N. Darrow is Chairman of the New Fund Institute for Collaborative Cancer Research which is a non-profit that provides funding packages to a handful of the most highly regarded anti-cancer drug hunters who are based at the country’s most acclaimed academic research centers. An NFI award requires the scientists to work collaboratively for a decade and for their research center to agree that all new drugs generated by the collaboration will be monetized by NFI, with proceeds then returned to the research centers. Twelve years ago, after his mother died of cancer, Duncan also established a charity that provides professional counseling and other supportive care to newly-diagnosed cancer patients on Long Island (www.fightingchance.org); for this work he has been recognized in a Wall Street Journal profile (6/25/12) and in a Proclamation issued by the New York State Assembly. Duncan and his wife, Wendy, who is a journalist, split their time between New York City and Sag Harbor. Duncan also has been a Wall Street lawyer for 40 years and at present is senior counsel with the firm of Sidley Austin LLP.

Ann Dewitt is Senior Director of Investments at Sanofi-Genzyme Bioventures. Ann joined SGBV in 2013 with a background in biotech partnering and early stage investment. Prior to SGBV, Ann was Senior Director, Corporate Development at Permeon Biologics and led a collaboration with a large pharmaceutical partner. Previously, Ann was a Senior Associate at Flagship Ventures, an early stage venture capital firm investing in healthcare companies with over $900 million under management and was a Board observer for several portfolio companies. While at Harvard, she was an entrepreneur-in-residence at Highland Capital Management and a founding team member of Novophage Therapeutics (now Sample6). Post-doctorate, she worked at 3M Company in corporate research and in business units, including 3M Pharmaceuticals, and was a Technical Circle of Excellence Award winner.

Ann is also on the Life Sciences Council of Springboard Enterprises, an organization dedicated to building high-growth technology-oriented companies led by women.

Ann holds a B.S. from the University of Illinois Urbana-Champaign, a Ph.D. from MIT in systems biology, and an M.B.A. from Harvard Business School.

Dr. Joseph DiMasi is Director of Economic Analysis at the Tufts Center for the Study of Drug Development. The Center is an independent non-profit multidisciplinary research organization affiliated with Tufts University that is committed to the exploration of scientific, economic, legal, and public policy issues related to pharmaceutical and biotechnology research, development, and regulation throughout the world. Dr. DiMasi serves on the editorial board of Therapeutic Innovation and Regulatory Science, and has previously served on the editorial boards of the Drug Information Journal, the Journal of Research in Pharmaceutical Economics, and the Journal of Pharmaceutical Finance, Economics & Policy. Dr. DiMasi is an internationally recognized expert on the economics of the pharmaceutical industry. He has published in a wide variety of economic, medical, and scientific journals, and has presented his research at numerous professional and industry conferences. Dr. DiMasi testified before the U.S. Congress in hearings leading up to the FDA Modernization Act of 1997 and reauthorization of the Prescription Drug User Fee Act.

Dr. DiMasi’s research interests include the R&D cost of new drug development, clinical success and phase attrition rates, development and regulatory approval times, the role that pharmacoeconomic evaluations have played in the R&D process, pricing and profitability in the pharmaceutical industry, innovation incentives for pharmaceutical R&D, and changes in the structure and performance of the pharmaceutical and biotechnology industries.

Stephen Fawell recently joined AstraZeneca as Head of Oncology iScience with responsibility for target selection, drug discovery and optimization and plays a supporting role in translation efforts.

Steve obtained his Ph.D. at the University of Leeds UK, traveled to the US for a post-doctoral fellowship at Rutgers Medical School and then returned to the UK to the Imperial Cancer Research Fund (now CR-UK) in London. In 1990, he returned to the United States again, this time to join the biotechnology company Biogen where after forming and leading the oncology group at Biogen, Steve became Head of the Oncology Research Groups for the newly merged Biogen Idec, Inc. In his 15 years at Biogen Idec, Steve was involved in work associated with AvonexTM and AngiomaxTM, and his team took four new oncology drugs to IND and into clinical trials. In 2005, he joined Novartis Oncology (NIBR) as Drug Discovery Head in Cambridge, and in this role he led efforts that resulted in four INDs and supported an impending NDA. Steve joined Merck in 2010 as Vice President and Worldwide Franchise Discovery Head for Oncology, with responsibility for all preclinical Oncology Discovery and Strategy. During his stay at Merck the group advanced an ERK and HDM2 inhibitor and a PD1 mAb (KeytrudaTM) into the clinic.

Jose Maria Fernandez is the Director General of the Treasury at Spain’s General Secretariat of the Treasury and Financial Policy, within the Ministry of Economy and Competitiveness. His responsibilities include the issuance and management of Spain’s Central Government Debt, its risk and liability management, the treasury and cash operations, the coordination of Spain’s regional government public issuers, the Treasury’s IT and Resources management and a multiplicity of other public sector related financing programs.

Prior to his current position, Jose-Maria worked at MIT’s Laboratory for Financial Engineering developing securitization models for biotech R&D portfolios and for Kendall Rho LLC, a finance innovation firm. In addition to this, he has substantial experience in capital markets. He ran the Debt Capital Markets Global Origination department for Sovereigns, Supranational and Development Agencies at Credit Agricole Corporate and Investment Bank and he worked in, and led for three years, the Funding and Debt Management Department at the Spanish Treasury. Jose-Maria has also worked for the World Bank as a securities and debt capital markets expert, consulting for emerging governments on topics related to public debt issuance and management strategy.

Jose-Maria holds an MBA degree from MIT Sloan (Sloan Fellows Program in Innovation and Global Leadership), a Masters in Finance degree from the London Business School, a Masters in Portfolio Management degree from I.E.B. and Bachelor’s Degree in Economics and Business from CUNEF (Madrid). He was appointed State Economist and Trade Expert of the Spanish General Government in 1997.

Sandra Matrick Forman is a senior counsel at Proskauer in the Capital Markets Group, based in their New York office. Her practice focuses on representing investment companies, including business development companies (BDCs) and their investment advisors/management companies/sponsors, as well as investment banks raising capital for BDCs. She is one of a select group of lawyers who actively represent BDCs. Sandra also regularly counsels investment companies and public companies regarding their corporate governance and compliance issues.

Prior to joining Proskauer, Sandra worked at Harris & Harris Group as General Counsel, Chief Compliance Officer and Director of Human Resources (since August 2004) and as Corporate Secretary (since January 2009). Previously, she was an attorney in the Investment Management Group at Skadden, Arps, Slate, Meagher & Flom.

Sandra was an intern in the office of the General Counsel of the United States Department of Defense, Office of the Secretary of Defense, and for the Honorable Ronald S. Lew of the United States Federal District Court, Central District of California.

She was recently named a 2014 Woman of the Year by the National Association of Professional Women. She is actively involved in various boards and organizations, and serves the Jewish Federation of Northern New Jersey as Vice Chair of its Identity, Continuity and Engagement Committee and a member of its Central Planning and Allocation Committee.

John Frishkopf serves as a Managing Director, Treasurer, and Head of Asset Management at NewStar Financial. He also serves as a member of the firm’s Management and Underwriting Committees. He oversees the funding of the firm’s balance sheet, including the successful structuring and placement of nine securitizations totaling nearly $4 billion. Mr Frishkopf has 27 years of experience in the domestic and international debt capital markets. Prior to co-founding the Company, he was a Managing Director of Milford Associates, LLC, a turnaround and corporate restructuring advisory firm, which he started in 1999. The firm has worked in the United States and in Europe providing financial and operational turnaround and restructuring advice to middle-market companies as well as workout advice to lenders in a range of industries. In 1999, he was appointed Executive Vice President and Chief Financial Officer of VSZ, a.s. Kosice (the Slovak Steel Company) where he played a key role in its successful restructuring. In 1992, he co-founded Benson Oak & Company an investment banking boutique operating in the Czech and Slovak Republics. As a partner and lead transactor, he advised on the structuring and placement of over $4 billion of debt transactions. Prior to Benson Oak, he was a vice president at Citicorp’s North American Investment Banking and International Corporate Finance Division where he spent five years working in capital markets, originating, structuring and placing securitization, loan and private placement deals. Mr. Frishkopf is a member of the board of directors of the National Brain Tumor Society and an advisor to Accelerate Brain Cancer Cure. He holds a B.S. from the Massachusetts Institute of Technology and an M.M.S. from the MIT Sloan School of Management.

Ilan Ganot is Founder, CEO and member of the board of directors for Solid Ventures. Prior to starting Solid, Mr. Ganot was an investment banker at JPMorgan Chase in London, specializing in hedge funds driven equities business for the firm. Ilan also work at Nomura Securities in London, Hong Kong and New York and Lehman Brothers in Europe.

Mr. Ganot embarked on a banking career after practicing law at leading Israeli firm, Haim Zadok & Co, where his focus was private equity law and mergers and acquisitions. Mr. Ganot was a captain in the Israel Defense Forces. Mr. Ganot received his MBA from London Business School and holds law and business degrees from the IDC in Herzliya, Israel.

Michael Goldberg graduated Summa Cum Laude with a Hon. B.Sc. in Biological Chemistry from the University of Toronto and received an M.Phil. in BioScience Enterprise from the University of Cambridge. Dr. Goldberg completed his Ph.D. in Biological Chemistry under the supervision of Institute Professor Robert Langer at the Massachusetts Institute of Technology, where he was a member of the founding class of the Harvard-MIT Division of Health Sciences and Technology’s Graduate Education in Medical Sciences program. His doctoral research focused on the synthesis, screening, and application of a novel class of materials for delivery of RNAi therapeutics. He pursued post-doctoral training in the laboratory of Institute Professor Phillip Sharp in the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology, where he worked to develop cancer-specific RNAi therapeutics targeting alternative splicing and synthetic lethality. Dr. Goldberg is presently an Assistant Professor in the Department of Cancer Immunology & AIDS at Dana-Farber Cancer Institute, Harvard Medical School. His lab creates novel drug delivery platforms for applications in cancer immunotherapy, as induction of antitumor immunity can lead to curative outcomes.

José-Carlos “JC” Gutiérrez-Ramos, Ph.D., is Senior Vice President and Head of BioTherapeutics Research & Development, within Pfizer Worldwide Research & Development. JC is passionate about the early and iterative use of experimental medicine approaches in discovery research, the continuous focus on scientific innovation and medical differentiation during drug discovery, and the “entrepreneurialization” of big pharma research groups.

Prior to joining Pfizer, JC was Senior Vice President and Head of the Immuno-inflammation Center for Drug Discovery (iiCEDD) at Glaxo Smith Kline. JC built the iiCEDD as a global group of “drug hunters” that included biologists, chemists, pharmacologists, protein scientists, clinicians and business developers who were responsible for drug discovery and development through Phase IIa (Proof of Concept). Chief achievements in the formation of the iiCEDD included entrepreneurial organizational and funding structure, the talent recruitment and identification of innovative discovery areas to focus on, which were poised for medical differentiation. The iiCEDD pipeline had a significant external component with 50 percent of its pipeline and activities achieved through external partnerships with biotech companies, academia and contract research organizations.

Prior to GSK José-Carlos served as Site Head and Chief Scientific Officer (CSO) at AMGEN Mountain View. Previous to the AMGEN acquisition of Avidia, he was the Senior Vice President of R&D, where he led a significant effort of novel protein therapeutics for autoimmune disease. Before his AVIDIA appointment, he served as CSO of Peptimmune Inc. in Cambridge, MA, where he was responsible for the development of peptide based therapeutics for autoimmune disease, including multiple sclerosis and diabetes. Before Peptimmune, JC served as Vice President, Inflammation at Millennium Pharmaceuticals, where he was responsible for advancing preclinical candidates in Inflammation & Immunology to human trials and advancing compounds (small molecules and antibodies) from discovery through clinical development.

JC was also part of the Faculty at the Genetics department of Harvard Medical School, where he led a major research team at the Center for Blood Research that generated more than 150 peer-reviewed publications. Before coming to the US, he was member of the Basel Institute for Immunology in Basel, Switzerland, and a fellow at the Max-Planck for Immunbiologie in Freiburg, Germany. JC received his master’s degree in Chemistry and his Ph.D. in Immunochemistry by the Autonoma University of Madrid, Spain.

Tyler Jacks is the Director of MIT’s Koch Institute for Integrative Cancer Research and the David H. Koch Professor of Biology at MIT. He has pioneered the use of gene targeting technology in the mouse to study cancer-associated genes and to construct mouse models of many human cancer types, including cancers of the lung, brain and ovary. His lab has made seminal contributions to the understanding of the effects of mutations of several common cancer-associated genes. This research has led to novel insights into tumor development, normal development and other cellular processes, as well as new strategies for cancer detection and treatment.

Jacks has published more than 200 scientific papers. He has served on the Board of Scientific Advisors of the National Cancer Institute (NCI) and the Board of Directors of the American Association of Cancer Research (AACR); he is also a past president of the AACR. He is currently chair of the National Cancer Advisory Board. Jacks is a member of the Board of Directors of Amgen and Thermo Fisher Scientific and an advisor to several biotechnology and pharmaceutical companies.

In recognition of his contributions to the study of cancer genetics, he has received numerous awards, including the AACR Outstanding Achievement Award, the Amgen Award from the American Society of Biochemistry and Molecular Biology, the Chestnut Hill Award for Excellence in Medical Research, the Paul Marks Prize for Cancer Research and in 2013 was named one of the MGH’s Cancer Center’s One Hundred. He was elected to both the National Academy of Sciences and the Institute of Medicine of the National Academies in 2009, the American Academy of Arts and Sciences in 2012, and the inaugural class of Fellows of the AACR Academy in 2013. Jacks was a Merck Fellow of the Helen Hay Whitney Foundation, a Markey Scholar, a Searle Scholar, and is currently a Daniel K. Ludwig Scholar in Cancer Research and a Howard Hughes Medical Institute Investigator. Jacks received his BA in biology from Harvard College in 1983. His PhD thesis was performed with Harold Varmus at the University of California, San Francisco. He served as post-doctoral fellow in Robert Weinberg’s lab at the Whitehead Institute at MIT and joined the MIT faculty in 1992.

Alan L. Jakimo, senior counsel in Sidley Austin’s New York office, works in the corporate, securities, venture, and technology fields, with emphasis in the life science and information science industries. Mr. Jakimo’s experience encompasses a broad range of transactions in venues spanning the Americas, Asia, and Europe and involving financial institutions and operating enterprises along the spectrum from start-up to seasoned. The interplay among finance, technology development, and licensing of intellectual property rights plays a key role in many of Mr. Jakimo’s assignments. He serves as a Special Professor of Law at Hofstra Law School, where he teaches a course on the influence of law and regulation on the discovery, development, and commercialization of regulated medical products.

Edward Jung founded Intellectual Ventures after leaving Microsoft Corporation where he was chief architect and advisor to executive staff. At Intellectual Ventures, he also serves as the chief technology officer, setting strategic technology and new business models for the company.

At Microsoft, Mr. Jung managed projects relating to web platforms, semantic web technology, intelligent operating systems, adaptive user interfaces and artificial intelligence. He co-founded many Microsoft teams including Windows NT, Microsoft Research, mobile and consumer products, and web services. Before joining Microsoft in February 1990, Mr. Jung founded the Deep Thought Group, working on neural network chips for learning and parallel computation. His biomedical research work in the 1980s in protein structure and function was published in several journals including the Proceedings of the National Academy of Sciences and the Journal of Biochemistry.

An avid inventor, Mr. Jung holds more than 700 patents worldwide and has over 1,000 patents pending. His inventions are in the areas of biomedicine, computing, networking, energy, and material sciences.

Mr. Jung has served as an advisor to Harvard Medical School, the Fred Hutchinson Cancer Research Center and the Institute for Systems Biology and consulted to the Asia Pacific Federation, the Aspen Institute, the China Academy of Sciences, the National Academy of Sciences, and the World Health Organization.

Jeb Keiper was recently appointed Chief Business Officer of Nimbus Discovery, a Series A biotech firm based in Cambridge, MA.

Prior to joining Nimbus Discovery, Jeb was Vice President (VP) of Business Development for GSK Oncology and a member of the Oncology Executive team as well as the Worldwide Business Development Leadership Team. In this role, Jeb was responsible for defining and executing the business development strategy for GSK Oncology, including in‐licensing transactions, acquisitions, strategic alliances, academic research relationships, alliance management and competitive intelligence. Alongside these responsibilities, Jeb was also named to lead the GSK-Novartis integration of the commercial oncology business valued at $16B and impacting thousands of staff across 80+ countries.

Jeb joined GSK in 2005 as RADEX Secretary for R&D Chairman Moncef Slaoui. In 2008, he moved to Worldwide Business Development (WWBD) where he held multiple roles in early- and late-stage licensing opportunities, commercial collaborations, out-licensing, newco spinouts, and public and private equity transactions. Jeb also helped to establish the WWBD Transactions Centre of Excellence for GSK as Head of Acquisitions and Divestments.

Prior to joining GSK, Jeb worked in business development at Boston-based TransForm Pharmaceuticals (bought by J&J in 2005 for $230 million), as well as for McKinsey & Company, a management consultant firm serving pharma and biotech clients. Jeb began his career at Pfizer Central Research as a chemist. He received four degrees from the Massachusetts Institute of Technology (MIT) in Chemistry, two in Chemical Engineering, and an M.B.A. from the MIT Sloan School of Management with joint program in Biomedical Enterprises with Harvard Medical School.

Manolis Kellis is a Professor of Computer Science at MIT, a member of the Computer Science and Artificial Intelligence Laboratory and of the Broad Institute of MIT and Harvard, where he directs the MIT Computational Biology Group. His group works at the interface of computational and experimental genomics, and has pioneered methods for characterizing the regulatory elements of the human genome, and their role in human disease using comparative genomics, epigenomics, and regulatory genomics. His group has helped lead the integrative analysis efforts of several large-scale genomics projects, including the NIH Roadmap Epigenomics project, the ENCODE project, the comparative analysis of 29 mammals, and the Genotype Tissue-Expression (GTEx) project. He has received the US Presidential Early Career Award in Science and Engineering (PECASE), the NSF CAREER award, the Alfred P. Sloan Fellowship, and was recognized as a top young innovator by Technology Review, Genome Technology, and the Boston Museum of Science. He obtained his Ph.D. from MIT, where he received the Sprowls award for the best doctorate thesis in computer science. Prior to computational biology, he worked on artificial intelligence, machine vision, robotics, and computational geometry, at MIT and at the Xerox Palo Alto Research Center. He lived in Greece and France before moving to the US.

Gary J. Kelloff, MD has had over 40 years in cancer research at the National Cancer Institute (NCI), authoring more than 400 publications. Dr. Kelloff is a graduate of the University of Colorado (BS and MD degrees). After post-graduate training in medicine at Emory University, he began his NCI career as an intramural scientist and section head in viral immunology working on retroviruses and oncogenes. After fifteen years in NCI’s intramural program he moved to what is now the Division of Cancer Prevention (DCP), where he developed a basic science, translational research, and clinical development program in chemoprevention. Since 2001, he has been a special advisor for the NCI Division of Cancer Treatment and Diagnosis working on strategies for developing imaging-based and clinical biomarkers for oncology drug development and cancer patient management. He previously led and currently leads several collaborations with FDA and the pharmaceutical industry on drug development strategies and co-chairs on-going efforts under the Foundation for the National Institutes for Health Biomarkers Consortium to define biomarker use in cancer drug development and patient management. Past work has included establishment of a developmental pathway for approval of cancer prevention drugs as part of an AACR initiative and evaluation of tumor burden markers (PSA-doubling time prostate cancer, Ca-125 in ovary) and precancerous histopathology (colorectal adenomas) as part of a C Change initiative. Current efforts under the Biomarkers Consortium include consideration of functional and molecular imaging (FDG-PET/CT, volumetric CT, DW-MRI, molecular probes) and new technologies for measuring circulating tumor cells, minimal residual disease, novel trial designs for evaluating prognostic and predictive biomarkers, molecular signatures and new drugs, including gene expression and proteomic biomarkers. All this work has involved collaboration with leaders in industry, academia, and the pharmaceutical industry and has resulted in many publications addressing specific biomarkers and general drug development strategies.

S.P. Kothari is Deputy Dean and Gordon Y Billard Professor of Accounting and Finance at the Sloan School of Management. As Deputy Dean, he has responsibility for all of Sloan’s faculty, approximately 200 (hiring, promotion and tenure, performance evaluation, and compensation), and half a dozen research centers based in Sloan.

Previously, he served as global head of equity research for Barclays Global Investors (BGI), responsible for research supporting BGI’s active equity strategies, from 2008-09. The actively managed equity portfolio had in excess of $100 billion in assets, and the research team was comprised of approximately 50 PhDs based in San Francisco, London, and Sydney.

Earlier, Kothari was Head of the Department of Economics, Finance, and Accounting at the MIT Sloan School of Management. This department included approximately 75 professors and lecturers and an administrative staff.

Kothari’s highly cited research focuses on financial reporting and valuation, asset allocation, explaining the diversity in international accounting practices, use of employee stock options for compensating executives and accounting for stock options, evaluating investment performance, and corporate uses of derivatives for hedging and speculation. The American Accounting Association (AAA) honored his work with the 2014 Notable Contributions to Accounting Literature Award. For the past 17 years, Kothari has served as an editor of the Journal of Accounting & Economics, a world-renowned academic research journal in accounting. He is an expert on economic policy issues in India and has written numerous opinion-page editorials in The Economic Times.

Kothari has frequently served as a senior consultant with Charles River Associates (www.crai.com), a business-economics and litigation-support consulting firm. He has consulted with many large corporations, including leading U.S. and international banks and asset management companies, Australian television broadcast corporations, U.S. steel companies, E&Y, KPMG, PriceWaterhouse Coopers, and the U.S. Department of Justice. Kothari served on the Board of VVisions (http://vvisions.com/) from 1998-2004 and is currently on the Board of FIA Global (http://www.fiaglobal.com/).

Kothari received his BE (Hons.) from the Birla Institute of Technology & Science, Pilani; his MBA from the Indian Institute of Management, Ahmedabad; and his PhD from the University of Iowa. He has also received an honorary doctorate, Doctor Honoris Causa, from the University of Technology, Sydney, in May 2013, and a Distinguished Alumnus Award from Birla Institute of Technology and Science, Pilani, in 2013.

Eric Lander is a geneticist, molecular biologist and mathematician, who pioneered many of the key concepts for discovering the genes underlying human diseases and helped to bring them into reality as one of the principal leaders of the international Human Genome Project.

He is Founding Director of the Broad Institute of Harvard and MIT, as well as Professor of Biology at MIT and Professor of Systems Biology at Harvard. Previously, he directed the Whitehead/MIT Center for Genome Research, the largest center in the Human Genome Project.

His research has ranged over all aspects of the human genome — including the genetic basis of inherited diseases and cancer, human population history, evolutionary forces, regulatory elements, long non-coding RNAs, and three-dimensional folding of the genome.

The recipient of numerous awards, he was elected a member of the US National Academy of Sciences and Institute of Medicine.

Dr. Lander was appointed by President Obama to co-chair the President’s Council of Advisors on Science and Technology, which advises the White House on matters including health, manufacturing, energy, communications, nanotechnology and national security.

Dr. Lander earned his BA from Princeton and PhD from Oxford as a Rhodes Scholar. He has co-founded several successful biotechnology firms.

Clifton Leaf is Deputy Managing Editor at Fortune, where he helps oversee the magazine as well as edits major features. A former Executive Editor at Fortune, Cliff rejoined the magazine in October 2013 after a six-year hiatus. During that time he served as a guest editor for The New York Times op-ed page and Sunday Review and, prior to that, as Executive Editor at SmartMoney magazine.

A winner of the Gerald Loeb Award for Distinguished Business and Financial Journalism and a two-time finalist for the National Magazine Award, Cliff has devoted much of the past decade to a cause somewhat removed from business journalism: trying to change the way the global war on cancer is funded and pursued. That effort culminated in his well-received book, The Truth in Small Doses: Why We’re Losing the War on Cancer—and How to Win It, which was published by Simon & Schuster in the summer of 2013.

A keynote or featured speaker at more than three dozen scientific conferences around the world, Cliff has presented testimony to the President’s Cancer Panel three times, served on the national board of directors for Susan G. Komen for the Cure, the world’s largest breast cancer charity, and delivered “Grand Rounds” at the National Cancer Institute. He is a recipient of the NIHCM’s Health Care Journalism Award, the Andrew Heiskell Community Service Award, and several leadership honors from patient organizations. And this July, the European School of Oncology gave Cliff its first Lifetime Achievement Award for cancer reporting, “in recognition of his contribution over more than a decade to opening up informed and critical debate about the way cancer research efforts are organized and conducted.”

Prior to joining Fortune in 2000, Cliff was an editor and writer for a number of national magazines. A graduate of Williams College, he later received a Master of Fine Arts in writing from Sarah Lawrence College. He lives in Brooklyn, New York, with his wife, filmmaker Alicia Slimmer, and their 10-year-old daughter, Sofia.

Pablo Legorreta, Royalty Pharma, please follow link for bio.

Bruce N. Lehmann is a professor of finance and economics in the Graduate School of International Relations and Pacific Studies of the University of California, San Diego. Prior to joining IR/PS in 1992, he was on the faculty of the Department of Economics and the Graduate School of Business at Columbia University for eleven years. Professor Lehmann is a specialist in financial economics, with expertise in the pricing of capital assets, their volatility, and the markets in which they trade. His main research interests include empirical tests of asset pricing models, the analysis of short-run stock price fluctuations, and the microstructure of securities markets, with recent emphasis on the behavior of Japanese financial markets. Lehmann is the author of numerous articles in leading scholarly journals, including the Journal of Finance; the Journal of Financial Economics; Macroeconomic Dynamics; the Quarterly Journal of Economics; and the Journal of Econometrics. He is also the author of the entry “Empirical Testing of Asset Pricing Models” in the New Palgrave Dictionary of Money and Finance. Lehmann is founding co-editor of the Journal of Financial Markets and has served as associate editor of the Review of Financial Studies and the Review of Quantitative Finance and Accounting. He has served as a director of the Western Finance Association, a member of the Scientific Advisory Board of Investment Technology Group, Inc. and on the boards of directors of First Boston Investment Funds, Inc. and of BEA Associates, Inc. Lehmann currently serves on the Investment Advisory Board of the University of California Retirement System and Endowment and on the Investment Committee of the UC San Diego Foundation. He has earned many honors and distinctions: he was a Batterymarch Fellow, the most prestigious award given to scholars in finance; an Olin Fellow at the National Bureau of Economic Research; and a National Fellow at the Hoover Institution on War, Revolution and Peace at Stanford University. He is the only person to receive all three distinctions. He is currently actively exploring early stage drug development based on the megafund concept.

He earned his A.B. in economics and history magna cum laude from Washington University and his M.A. and Ph.D. degrees in economics from the University of Chicago.

Judy Lewent, please follow link for bio.

Dr. Aili (Alison) Li is a Portfolio Manager in Asset Allocation/Risk Management at the California Public Employees’ Retirement System (CalPERS). At CalPERS, the Asset Allocation unit is responsible for strategic as well as tactical asset allocation of the Total Fund. Her work involves theory verification, hypothesis development, empirical testing of valuation framework and risk management for all asset classes in the Total Fund, including public and private equity, fixed income, real assets and hedge funds.

Before CalPERS, Dr. Li worked for WorldQuant LLC in 2012 as Vice President in Portfolio Management. She was in charge of building quantitative equity long-short strategies as part of a multi-billion dollar multi-strategy hedge fund.

From May 2007 to October 2010, Dr. Li was director of equity research at Symphony Asset management LLC. She was in charge of the entire quantitative equity investment process with three billion under management at its peak.

From September 2001 to May 2007, Dr. Li was quantitative equity strategist at Mellon Capital Management Corp. She built alpha factors for quantitative equity and global tactical asset allocation strategies.

From August 1998 to August 2001, Dr. Li was Assistant Professor of Accounting at the Hong Kong University of Science and Technology.

Dr. Li received her Ph.D. in Business Administration with concentration in Accounting and Finance from Haas School of Business, U.C. Berkeley. She received her Master in Economics from University of Southern California. She got her B.A. in Investment and Management from Renmin University of China.

Andrew W. Lo is the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management, the director of MIT’s Laboratory for Financial Engineering, a principal investigator at MIT’s Computer Science and Artificial Intelligence Lab, and an affiliated faculty member of the MIT Department of Electrical Engineering and Computer Science. He received his B.A. in economics from Yale University in 1980, his A.M. and Ph.D. in economics from Harvard University in 1984, and taught at the University of Pennsylvania’s Wharton School from 1984 until 1988 when he joined MIT’s faculty. He has authored many research articles (see http://web.mit.edu/alo/www) and several books including The Econometrics of Financial Markets, A Non-Random Walk Down Wall Street, and Hedge Funds: An Analytic Perspective. His most recent research interests include econometric methods for measuring and monitoring systemic risk, evolutionary and neurobiological models of investor behavior, and applications of financial engineering to support biomedical innovation and translational medicine.

Rosemarie Loffredo is the Chief Administrative Officer and Chief Financial Officer of Leukemia & Lymphoma Society (LLS). In her role, she ensures that LLS achieves the ambitious goals of its long-range strategic plan. Ms. Loffredo leads all administrative and staff functions, including finance, information technology and human resources, and she is responsible for enhancing LLS’s organizational efficiency and effectiveness in partnership with the organization’s executive team.

Earlier in her career, Ms. Loffredo served as interim chief financial officer for Pro Mujer International, a nonprofit organization dedicated to empowering disenfranchised women in Latin America through microfinance, healthcare and educational services. She previously served as vice president, financial operations and treasurer of New York University, the largest private research university in the U.S. She also served as senior vice president of finance for CA Technologies, Inc. (formerly Computer Associates), one of the world’s largest enterprise management software providers and prior to that position was vice president of treasury for International Paper Company. She previously held leadership positions with global banks in international treasury as well industry segment management including securities and commodities, capital-intensive industry and public finance. Ms. Loffredo currently serves on the board of directors of CenterLight Healthcare System.

Ms. Loffredo holds a bachelor’s degree in international economics, commerce and finance from Georgetown University, a master’s degree in economics from Boston College, and an M.B.A. in finance and international business from Columbia University.

Juan Carlos López was born in Oaxaca, México, in 1967. He obtained his first degree on Biomedical Research at the Universidad Nacional Autónoma de México, majoring in neuroscience. Juan Carlos got his Ph.D. degree from Columbia University (New York) in the laboratory of Eric Kandel, studying synaptic plasticity in neuronal cultures. He then carried out postdoctoral work at the Instituto Cajal (Madrid), studying presynaptic mechanisms of transmitter release. During this period, Juan Carlos wrote a book on the neurobiology of memory (“El Telar de la Memoria”, Algar Editorial), with which he won the IV European Award of Scientific Dissemination in 1998. Two years later, Juan Carlos left experimental research to become Editor of Nature Reviews Neuroscience in London. In January 2004, he returned to New York to become the Chief Editor of Nature Medicine.

In February 2014, Juan Carlos left the publishing industry to become Head of Academic Relations and Collaborations at Hoffmann-La Roche. In this role, he and his team are charged with fostering interactions of his company with academic institutions worldwide with the aim of promoting the advance of translational research and the discovery of new medicines.

Juan Carlos has also served as a member of the Scientific Advisory Board and of the Board of Directors of Noscira, a Spanish biotechnology company interested in neurodegeneration, and a member of the Board of Directors of the Eureka Institute, an international initiative that aims to promote translational research by fostering the education of MDs and PhDs interested in bridging the gap between bench and bedside.

Anna A. Makki is a Director within the Credit Suisse Asset Finance Group in New York, with ten years of capital markets and investment banking experience. She specializes in securitizing “off-the-run” asset classes, with a particular focus on monetizing pharmaceutical royalties. In her career, Anna has raised over $1.5 billion for clients including biopharmaceutical companies, research institutions, inventors and healthcare royalty investors.

Prior to joining Credit Suisse, Anna was an Executive Director within Morgan Stanley’s Global Capital Markets division, specializing in structured debt financings and intellectual property monetizations. Previously, she spent several years within Investment Banking where she focused on M&A and capital raising transactions for insurance clients. She started her investment banking career at Banc of America Securities in New York.

Anna graduated from Franklin & Marshall College, Magna Cum Laude and Phi Beta Kappa, with a B.A. in mathematics and business administration. She received a M.B.A. from The Wharton School and a M.A. from the Lauder Institute of Management & International Studies at the University of

Parag Mallick’s primary appointment is as an Assistant Professor at Stanford University. Dr. Mallick received his undergraduate degree in Computer Science and Biochemistry from Washington University in St. Louis, and his graduate degree with David Eisenberg at UCLA. His postdoctoral research, with Ruedi Aebersold at the Institute for Systems Biology, focused on quantitative and clinical proteomics. His current research interests focus on development of tools for quantitative, proteome-scale analyses of protein structure and function and on the application of those tools to global profiling for predictive, personalized cancer diagnosis and prognosis. His research bridges the interface between experimental studies and analytic computational challenges.

Dr. Monique Mansoura is the Senior Director of the Medical Countermeasures Franchise at Novartis Vaccines (NVx) leading daily operations and policy for a cross-functional, global team with a portfolio of contracts that make Novartis one of the premier partners of the U.S. Government mission to development medical countermeasures in support of its critical role in national and global health security. She is an active member in leading multi-stakeholder coalitions working to strengthen these public-private partnerships that are central to this vital mission.

Dr. Mansoura has a passion and track record of success in building and developing high performing, cross-functional teams driven to tackle, design and drive complex missions of international importance with expertise at the interface of public-private partnerships, particularly in market-challenged environments. She has been a successful leader at top levels of Government and industry by building effective teams across diverse organizations, developing talent, leveraging multi-stakeholder networks through effective engagement with partners including senior leaders in the Executive Office of the President, executive branch agencies (HHS, DHS, DOD), Congress, industry, academia, patient advocacy organizations and state, local and international governments.

She trained under Francis Collins at the National Institutes of Health (NIH) during the peak of activity for the Human Genome Project (1996-2001) and following 9/11 and the anthrax attacks in 2001, took on leadership roles in National Health Security for the U.S. Government (USG). From 2002-2010 she drove strategic policy, programming and budgeting for a pioneering multibillion dollar medical countermeasure (MCM) development and acquisition program under the authorities of the Project BioShield Act of 2004 and the Pandemic and All-Hazards Preparedness Act of 2006. She led development of the inaugural Public Health Emergency Medical Countermeasure (PHEMCE) Strategy and Implementation Plan which provided the framework for priority-setting and a roadmap for the allocation of the $5.6 billion fund to enhance preparedness against chemical, biological, radiological and nuclear threats during the first decade of the program.

Dr. Mansoura earned a Ph.D. in Bioengineering and M.S. in Human Genetics from the University of Michigan and a B.S. in Chemical Engineering from Wayne State University. During a recent sabbatical, she earned an MBA in the MIT Sloan Fellows Program in Innovation and Global Leadership, served as a consultant to the MIT Center for Biomedical Innovation and supported program and planning efforts for the NIH Therapeutics for Rare and Neglected Diseases (TRND) program, now a part of the National Center for Advancing Translational Science (NCATS) at NIH.

Cyrus Mehta is President and co-founder of Cytel Corporation and Adjunct Professor of Biostatistics, Harvard University. Cytel is a leading provider of software and services for the design, interim monitoring and implementation of adaptive clinical trials. Dr. Mehta consults extensively with the biopharmaceutical industry on group sequential and adaptive design, offers workshops on these topics, and serves on data monitoring and steering committees for trials in many therapeutic areas including oncology, cardiology, neurology and metabolic disease. He has led the development of the StatXact, LogXact and East software packages that are widely used in the biopharmaceutical industry and at academic research centers. He publishes his methodological research in leading statistics journals and is a past co-winner of the George W. Snedecor Award from the American Statistical Association. He is a Fellow of the American Statistical Association and an elected member of the International Statistical Institute. He was named Mosteller Statistician of the Year by the Massachusetts Chapter of the American Statistical Association in 2000, and Outstanding Zoroastrian Entrepreneur by the World Zoroastrian Chamber of Commerce in 2002.

Michael Millette is the global head of the Structured Finance business in the Finance Group at Goldman Sachs. He is also co-chairman of the Structured Finance Capital Committee and serves on the Investment Banking Division Client and Business Standards Committee and the Bank Capital Committee. Michael joined Goldman Sachs in 1994 in Fixed Income and moved to the Finance Group in 1997. He was named managing director in 2002 and partner in 2006.

Prior to joining the firm, Michael worked as an analyst at Citibank and a portfolio manager at John Hancock.

Michael serves on the Board of Visitors for the School of Business and Economics of the Catholic University of America, the Board of Trustees of the Inner City Scholarship Fund, the Board of Directors of the Massachusetts Boys and Girls State Foundation, the Publication Committee of the Manhattan Institute, the Finance Committee of The Ursuline School, and the Advisory Board of the Boston College Center for Asset Management.

Michael earned an AB in History from Cornell University in 1987 and an MS in Finance from Boston College in 1994. He became a CFA charterholder in 1994.

Stewart C. Myers is the Robert C. Merton (1970) Professor of Finance at the MIT Sloan School of Management.

His research is primarily concerned with the valuation of real and financial assets, corporate financial policy, and the financial aspects of government regulation of business. Myers is the author of influential research papers on many topics, including adjusted present value, rate of return regulation, pricing and capital allocation in insurance, real options, and moral hazard and information issues in capital structure decisions. He is the co-author of the classic textbook, Principles of Corporate Finance, now in its 11th edition.

Myers is past president of the American Finance Association and an elected Fellow of the Financial Management Association. He also is a Research Associate of the National Bureau of Economic Research; a principal of the Brattle Group, Inc.; and a director of Entergy Corporation.

Myers holds an AB from Williams College and an MBA and a PhD from Stanford University.

Larry Norton, Memorial Sloan Kettering Cancer Center, please follow link for bio.

Dr. Robert O’Neill is the Senior Statistical Advisor to CDER in the Office of Translational Sciences in the Center for Drug Evaluation and Research (CDER), Food and Drug Administration. Until June 2011 , Dr. O’Neill was the Director of the Office of Biostatistics which provides biostatistical and scientific computational leadership and support to all programs of CDER. Prior to October 1998 he was Director of the Office of Epidemiology and Biostatistics, responsible also for the post-market safety surveillance of new drugs. In 1989-1990, Dr. O’Neill was a visiting professor at the Department of Research, University Medical School, Basel, Switzerland, where he developed and presented numerous lectures and created a course series ‘Topics in Therapy Evaluation and Review ‘ (TITER) for European pharmaceutical scientists, which was the model for the European Course In Pharmaceutical Medicine (ECPM), a degree granting graduate program. Dr. O’Neill was the ICH FDA topics leader for two guidances, E9 and E5. He is a fellow of the American Statistical Association (1985) and the Society for Clinical Trials (2013), a member of several professional societies, a past Member of the Board of Directors of the Society for Clinical Trials, the 2002 recipient of the Marvin Zelen Leadership Award in Statistical Science, and the 2004 Lowell Reed Lecture Awardee from the American Public Health Association.

Karen Shaw Petrou was dubbed by the American Banker in 2012 the “sharpest mind analyzing banking policy today — maybe ever.”

She is the co-founder and Managing Partner of Federal Financial Analytics, Inc., a privately-held company that, since 1985, has provided analytical and advisory services on legislative, regulatory, and public-policy issues affecting financial services companies doing business in the U.S. and abroad. The firm’s practice is a unique blend of strategic advice and policy analysis that does not include lobbying or any other projects that would compromise its objectivity and independence. This, Petrou believes, gives boards of directors, senior management and regulators the best advice on emerging issues on which to base their own strategic planning and advocacy.

Ms. Petrou is a frequent speaker on topics affecting the financial services industry. In addition to presentations to Congress, foreign legislatures and government agencies, she has spoken before such organizations as the Japanese Diet, the Office of the Comptroller of the Currency, various Federal Reserve Banks, the Economist’s Buttonwood conference, the Securities Industry and Financial Markets Association, the American Bankers Association, The Clearing House, the Financial Services Roundtable, the Institute of International Bankers, the Conference of State Bank Supervisors, the American Bar Association, the Brookings Institution, the American Institute of Certified Public Accountants, the National Association of Manufacturers, and many other industry, academic and policy-maker audiences. She has also authored numerous articles in professional publications such as the American Banker and International Economy, as well as general-interest media like The New York Times and Wall Street Journal. Ms. Petrou appears frequently in the media as an expert on banking legislation and regulation.

Prior to founding her own firm in 1985, Ms. Petrou worked in Washington as an officer at Bank of America, where she began her career in 1977. She is an honors graduate in Political Science from Wellesley College and also was a special student in an honors program at the Massachusetts Institute of Technology. She earned an M.A. in that subject from the University of California at Berkeley, and was a doctoral candidate there. She has served on numerous boards of banking organizations and sits as a director on the board of the Foundation Fighting Blindness and as an advisory member of the board of the Morin Center for Banking and
Financial Law.

Syril Pettit is the Executive Director of the ILSI Health and Environmental Sciences Institute (HESI). HESI is a global, non-profit organization based in Washington, DC, that provides a platform for scientists from academia, government, industry, NGOs, and other research organizations to collaborate in addressing human and environmental health issues. HESI’s scientific initiatives develop multi-sector derived data and technical approaches to support improved public health via enhanced drug, chemical, environmental, and food safety and innovation. Syril is the senior staff leader of HESI’s efforts to engage scientists from more than 80 universities, 40 government agencies, and 50 companies from around the globe in its programs.

Syril provides scientific and strategic leadership to the organization’s 16 different technical programs in such areas as cardiovascular safety, genetic toxicology, risk assessment methodology, bioaccumulation, immunotoxicology, and more. As Executive Director, Syril works closely with HESI’s program 7 management staff in-house (all with advanced scientific degrees) as well as via interactions with the hundreds of scientific experts who participate in HESI’s international programs. She helps to ensure the technical rigor, efficiency, and balance of HESI’s initiatives as well as supporting efforts to ensure their effective communication to the scientific community.

Syril routinely speaks at international scientific meetings, as a lecturer at government and academic institutes, and has authored numerous scientific articles published in journals such as Science Translational Medicine, Toxicological Sciences, American Heart Journal, etc. Over the last year she launched HESI’s CITE (Combining Interdisciplinary and Translational Expertise) initiative that has helped establish HESI’s role in providing international thought-leadership and expertise in moving research to public health application across diverse sectors. Syril has been a staff member of HESI for 14 years and Executive Director since 2011. She holds a bachelor’s degree in Biology from Amherst College and a Master’s Degree in Environmental Management from the Duke University Nicholas School of the Environment. She served as a Counselor for the National Capital Area Chapter for the Society of Toxicology (for 5 years), and is currently a member of the Duke NSOE Alumni Counsel. She is an avid swimmer and marathoner.

Cathrin Petty joined J.P. Morgan in 2014 to co-head the healthcare team. She has extensive experience in the life sciences industry and has nearly twenty years experience in private equity, investment management and investment banking. She has invested over $1 billion in 28 companies in EU, US and India in the pharmaceutical, biotechnology, medical technology and generics sectors. Cathrin is a Non-Executive Director of Circassia Pharmaceuticals plc. She was recently a Non-Executive Director at ICON Plc and Non-Executive Director of the NHS Strategic Health Authority for Greater London.

Prior to joining J.P. Morgan, Cathrin was a Special Partner at Vitruvian Partners LLP, a Partner at Apax Partners LLP and Principal at Schroder Ventures Life Sciences . She holds an MA in Natural Sciences from the University of Cambridge and a post-graduate Diploma in Management Studies from the Judge Institute, Cambridge.

Tomas J. Philipson is the Daniel Levin Professor of Public Policy Studies in the Irving B. Harris Graduate School of Public Policy at The University of Chicago. He is an associate member of the Department of Economics and a former senior lecturer at the Law School. His research focuses on health economics, and he teaches Masters and PhD courses in microeconomics and health economics at the University.

Philipson was born and raised in Sweden where he obtained his undergraduate degree in mathematics at Uppsala University. He received his MA and PhD in economics from the Wharton School and the University of Pennsylvania. He was a visiting faculty member at Yale University in the academic year 1994-95 and a visiting fellow at the World Bank in the winter of 2003.

Philipson has served in several public sector positions. He served in the second Bush Administration as the senior economic advisor to the head of the Food and Drug Administration (FDA) during 2003-04 and subsequently as the senior economic advisor to the head of the Centers for Medicare and Medicaid Services (CMS) in 2004-05. He served as a senior health care advisor to Senator John McCain during his 2008 campaign for President of the United States. In December of 2010, he was appointed by the Speaker of the US House of Representatives to the Key Indicator Commission created by the recent health care reform.

Philipson is the recipient of numerous international and national research awards. He has twice (in 2000 and 2006) been the recipient of the highest honor of his field: the Kenneth Arrow Award of the International Health Economics Association (for best paper in the field of health economics). In addition, he was awarded the Garfield Award by Research America in 2007 (for best paper in the field of health economics), The Prêmio Haralambos Simeonidisand from the Brazilian Economic Association in 2006 (for best paper in any field), and the Distinguished Economic Research Award from the Milken Institute in 2003 (for best paper in any field of economics). Philipson has been awarded numerous grants and awards from both public and private agencies, including the National Institutes of Health, the National Science Foundation, the Rockefeller Foundation, the Alfred P. Sloan Foundation, the John M. Olin Foundation, and the Royal Swedish Academy of Sciences.
Philipson is a founding editor of the journal Forums for Health Economics & Policy of Berkeley Electronic Press and has been on the editorial board of the journal Health Economics and The European Journal of Health Economics. His research has been published widely in all leading academic journals of economics such as the American Economic Review, Journal of Political Economy, Quarterly Journal of Economics, Journal of Economic Theory, Journal of Health Economics, Health Affairs, and Econometrica.

Philipson is a fellow, board member, or associate of a number of other organizations outside the University, including the National Bureau of Economic Research, the American Enterprise Institute, the Manhattan Institute (where he is chairman of Project FDA), the Heartland Institute, the Milken Institute, the RAND Corporation, and the USC Shaeffer Center for Health Economics and Policy. At the University of Chicago, he is affiliated with the John M. Olin Program of Law & Economics, the George J. Stigler Center for the Study of the Economy and the State, the Northwestern/University of Chicago Joint Center for Poverty Research, the Population Research Center, and the National Opinion Research Center (NORC). He was a member of the University-wide Council on Research in 2000-02 and is currently a member of the Advisory Committee to the University’s Office of Intellectual Property and Technology Transfer (UCTech).

Philipson has done executive consulting for both private corporations, including many U.S. Fortune 100 companies, as well as government organizations domestically and internationally. This has included work for the President’s Council on Science and Technology, the National Academy of Sciences, and the UK National Health Service. It has also included work for multi-lateral organizations such as the World Bank, the World Intellectual Property Organization, and the OECD. He is the co-founder of Precision Heath Economics LLC, on the honorary board of directors of the internet-based consulting firm the Round Table Group, on the board of directors of MedErr Inc, on the board of the Center for Medicine in the Public Interest, on the council of advisors for the Gerson-Lehrman Group, and a consultant for Compass-Lexecon, Bates White, and Analysis Group.

Philipson’s research is frequently disseminated through the popular press. He is a monthly op-ed contributor for Forbes magazine and frequently appears in numerous popular media outlets such as CNN, CBS, FOX News, Bloomberg TV, National Public Radio, New York Times, Wall Street Journal, Business Week, The Economist, Washington Post, Investor’s Business Daily, and USA Today. He is a frequent keynote speaker at many domestic-and international health care events and conferences. Philipson has been selected for inclusion in The International Who’s Who in The World.

Leslie Platt, JD, is President of the nonprofit Innovation Financing Roundtable. Mr. Platt is a nationally recognized life sciences attorney and executive with significant senior-level experience in the public, private, and nonprofit sectors and substantial focus on innovation finance, impact investment, and public-private partnerships in the health and technology sectors.

Leslie has structured and negotiated numerous agreements regarding the financing, conduct, and commercialization of biomedical research, the financing and construction of research facilities and housing projects, and the protection, valuation, and transfer of intellectual property and technology. He has drafted many provisions enacted into law and has provided direction, counsel, and guidance on diverse U.S. and international public policy issues, projects, financings, management and personnel issues, and regulatory compliance matters.

Leslie is currently a Principal in Leslie Platt & Associates, LLC, where he has provided strategic advisory services to a leading biopharmaceutical company and other organizations. Mr. Platt previously served as Counsel at Pillsbury Winthrop Shaw Pittman LLP; Principal at Ernst & Young LLP; Chief Operating Officer and General Counsel of The Institute for Genomic Research (TIGR); and Senior Vice President and General Counsel at the American Type Culture Collection.

In the federal government, Leslie served as Executive Assistant to the Director and Chief of Operations, Office of the Director, at the National Institutes of Health; as Deputy General Counsel-Legal Counsel at the Department of Health and Human Services, and as Counsel and Staff Director of the White House Agent Orange Working Group. Leslie earlier served as Associate General Counsel for Legislation at the Department of Housing and Urban Development. Mr. Platt was a Charter Member of the Federal Senior Executive Service and has received a number of awards for distinguished public service.

Leslie also served for years as Board Chairman of the BIO-sponsored BioJudiciary Project and as Chair of the Loudoun County, VA Science & Technology Cabinet. Leslie has taught legal and ethical aspects of bioscience management at George Mason University. He has authored a number of articles and is a frequent lecturer at industry conferences in the U.S. and around the world.

Issi Rozen, director of strategic alliances at the Broad Institute of Harvard and MIT, is responsible for partnering with the pharmaceutical industry and venture investors and developing new scientific and business collaborations. He is also responsible for initiating and establishing new ventures around innovative research projects and for licensing the institute’s intellectual property portfolio. He joined the Broad in 2011 after a career in the pharmaceutical industry. Before joining the Broad Institute, Rozen was director of corporate development at Resolvyx Pharmaceuticals, a venture-backed biotech start-up, where he headed business development efforts. Before that, he led the business analysis group at EMD Serono where he was responsible for evaluations of in-licensing and M&A opportunities as well as commercial analytics and forecasting. In addition, Issi is also an accomplished jazz guitarist and has released three recordings. He earned his M.B.A. at MIT’s Sloan School of Management.

Tom Rutledge is Head of Origination and Sourcing at Magnetar Capital. Prior to joining Magnetar in 2008, Mr. Rutledge was an Executive Director in JPMorgan’s US Structured Credit group. Before that, he served in investment and risk management roles at several investment management firms, including positions as CIO for Fixed Income at OTA Asset Management, Head of Risk Management and Quantitative Analysis at Boldwater Capital, and Analyst at New Bond Trading. He was also Head of Flow Research and eResearch at Deutsche Bank. Mr. Rutledge began his career as a fixed income derivatives trader and marketer at Merrill Lynch in New York and London.

He has also served as an adjunct professor at Boston College’s Carroll School of Management, teaching a course in derivatives and risk management in the graduate finance program.

Mr. Rutledge received a BA in English from Amherst College and an MBA from the MIT Sloan School of Management.

David Sabow is a Managing Director and the Head of Silicon Valley Bank’s National Life Sciences and Healthcare practice. In this role, David manages the deal teams across the U.S. and is responsible for developing and executing on the Bank’s Life Sciences strategy. Silicon Valley Bank’s Life Sciences practice is the leading provider of financing, cash management, and investment management solutions for a wide range of private and public companies in the Emerging Therapeutic, Medical Device, Diagnostic, Digital Health and Healthcare Services sectors.

Prior to joining Silicon Valley Bank, David spent 8 years in the Life Sciences Investment Banking practice at Canaccord Genuity, where he participated in public financings and M&A transactions with an aggregate deal value in excess of $1 billion. While at Canaccord, David worked on both domestic and cross-border transactions across the spectrum of Life Sciences and Healthcare. David graduated with honors from Santa Clara University with a BS in Economics and a BA in French.

Ken Schaner has practiced law for over 40 years, representing many for-profit and non-profit entities in the corporate and tax aspects of a wide variety of agreements, transactions, financings, licenses, mergers and acquisitions.

Ken began his career at the Internal Revenue Service’s (IRS) legislative and regulations division. During his time with the IRS, Ken worked on the 1969 Tax Reform Act and was one of the principal drafters of the new private foundation provisions.

In 1982, Ken co-founded Swidler Berlin, LLP. While a partner in that firm, he also served as managing member and chair of the corporate group. After Swidler Berlin’s merger with Bingham McCutchen, LLP in 2006, Ken remained a partner until 2008, when he formed a new firm to focus on representing tax-exempt organizations.

Since 1983, Ken has served as general counsel to the Cystic Fibrosis Foundation (CFF). In that capacity, Ken represented CFF in its first venture philanthropy transaction with Aurora Biosciences Corporation (now Vertex). Since then, Ken has represented numerous clients in venture philanthropy transactions and related legal matters. Ken also serves as general and outside counsel to many non-profits. He advises on the full range of issues faced by Section 501(c)(3), (c)(4) and (c)(6) organizations, including board governance, business, and tax-exempt compliance issues.

David Schmittlein is the John C Head III Dean and Professor of Marketing at the MIT Sloan School of Management.

His focus has been to broaden MIT Sloan’s global visibility, to work with the faculty in creating new high-quality management education programs, to develop enhanced educational opportunities for current students, and to develop and disseminate business knowledge that has impact and that will stand the test of time. He also has reached out to the many members of MIT’s alumni community to gain their valuable insights on MIT Sloan and management education.

Prior to his appointment at MIT Sloan, Schmittlein was the Ira A. Lipman Professor and Professor of Marketing at the Wharton School of the University of Pennsylvania from 1980 until 2007. He also served as Interim Dean during July 2007 and as Deputy Dean from 2000 to 2007, and was chair of the editorial board for Wharton School Publishing. His research assesses marketing processes and develops methods for improving marketing decisions. He is widely regarded for his work estimating the impact of a firm’s marketing actions, designing market and survey research, and creating effective communication strategies.

Schmittlein has served as a consultant on these issues for numerous firms, including American Express, American Home Products, AT&T, Bausch & Lomb, Boston Scientific, Ford Motor Company, Gianni Versace S.p.A., Hewlett-Packard, Johnson & Johnson, Lockheed Martin, Pfizer, Revlon, Siebe PLC, the Oakland Raiders, The Quaker Oats Co., and Time Warner. His work has been published in leading journals in marketing, management, economics, and statistics. In addition, he has been an area editor for Marketing Science and a member of the editorial board for the Journal of Interactive Marketing, the Journal of Marketing Research, Marketing Letters, and Marketing Science.

Schmittlein serves on the International Advisory Board for Groupe HEC, the Governing Board of the Indian School of Business, the International Advisory Board of Lingnan (University) College of Sun Yat-sen University, and the Advisory Board for the School of Economics and Management of Tsinghua University. He has served on the World Economic Forum’s Global Agenda Council for Marketing and Branding. He has been a Visiting Professor in the Faculty of Economics at Tokyo University and a Distinguished Scholar in Residence at Washington University’s John M. Olin School of Business. Schmittlein has received awards for his research, his editorial work, and his teaching. His observations and research have been cited often in the popular press, including Advertising Age, Business 2.0, BusinessWeek, China.com, Computerworld, Fortune, NPR’s Marketplace, People’s Daily Online, Reuters,The ABC Evening News with Peter Jennings, The Economist, The Financial Times, The Los Angeles Times, The Philadelphia Inquirer, The New York Times, The Wall Street Journal, U.S. News & World Report, and USA Today.

Schmittlein holds a BA in mathematics from Brown University and an MPhil and a PhD in business from Columbia University.

Azita Sharif, an engineer and entrepreneur, is the founder and CEO of DSI, a bio-informatics firm, headquartered in Cambridge, MA, focusing on products and solutions for drug discovery, oncology, pathology bio-banking and transplant surgical applications. The technology her firm has developed enables drug companies to make better resources allocation for cohort development through Biobanking.

Azita started her career in the semiconductor industry as an R & D Engineer, and later as a Product Manager. From Engineering, she made the transition to high technology investment and was selected as a Kauffman Fellow. She served her fellowship at Advent International Global Private Equity in Boston. Since then, she has been involved with many startups and investment management programs in both the US and Argentina. She has advised a number of seed-stage start-ups on writing business plans and seeking venture funds. As a result of her efforts, a number of these companies were able to close funding and grew to a successful exit. Azita also worked on the start-up of a new venture fund, Triton Venture Management, ($45 M under management), in Austin, TX.

Since the mid-1990s, she has served as a judge in the annual International Moot Corp., MIT and Harvard Business Plan Competitions. She also served as a Director of the Executive Board of the Women’s Leadership Initiative at the JFK School of Government at Harvard. She is a member of Springboard Enterprises, an organization dedicated to building high-growth technology-oriented companies led by women. Azita is a graduate of The University of Texas at Austin, Fletcher School of Law and Diplomacy and Harvard Business School.

Phillip A. Sharp is Institute Professor (highest academic rank) at the Massachusetts Institute of Technology and member of the Department of Biology and the Koch Institute for Integrative Cancer Research. He joined the Center for Cancer Research (now the Koch Institute) in 1974 and served as its director for six years, from 1985 to 1991, before taking over as head of the Department of Biology, a position he held for the next eight years. More recently, he was founding director of the McGovern Institute, a position he held from 2000 to 2004. His research interests have centered on the molecular biology of gene expression relevant to cancer and the mechanisms of RNA splicing. His landmark work in 1977 provided the first indications of “discontinuous genes” in mammalian cells. The discovery fundamentally changed scientists’ understanding of gene structure and earned Dr. Sharp the 1993 Nobel Prize in Physiology or Medicine. Dr. Sharp has authored over 400 papers. He is an elected member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society, and the Royal Society, UK. Among his many awards are the Gairdner Foundation International Award, the Lasker Basic Medical Research Award and the National Medal of Science. His long list of service includes the presidency of the AAAS (2013) and Chair of the Scientific Advisory Committee, SU2C Project, AACR. A native of Kentucky, Dr. Sharp earned a B.A. degree from Union College, Barbourville, KY, and a Ph.D. in chemistry from the University of Illinois, Champaign-Urbana. Dr. Sharp is a co-founder of Biogen (now Biogen Idec) and Alnylam Pharmaceuticals Inc.

Greg Simon is the CEO of Poliwogg, a financial services company creating unique capital market opportunities in healthcare and life sciences. He has held senior positions in both chambers of Congress and the White House, been a senior strategy consultant to a variety of international technology CEO’s, led a national patient advocacy nonprofit he co-founded with Mike Milken and served as a senior executive at a large pharmaceutical corporation. He has developed a reputation as a visionary strategist, a dynamic public speaker and writer, and as a knowledgeable analyst of emerging trends in healthcare, information technology, innovative drug research and development and patient advocacy.

Darren Snellgrove is Chief Financial Officer, VP of Finance and Operations for Johnson & Johnson Innovation. This includes the Innovation Centers located in San Francisco, Boston, London, and Shanghai and the J&J Development Corporation (JJDC). Darren also provides financial support and leadership to Janssen Healthcare Innovation (JHI) and Janssen Labs. Darren is well suited for this role with a solid understanding of complex deal structures, value creation, external partner experience, and a proven track record of success in a variety of financial leadership positions. His diverse experience that spans multiple operating companies, sectors, and business development finance has positioned him well to build a dynamic portfolio of external relationships that will help drive innovation.

Prior to joining the J&J Innovation Organization, Darren was VP of Finance and Procurement, CFO at Janssen AI. In September 2009, as part of an agreement with Elan Corporation, Johnson & Johnson formed a new company that acquired substantially all of Elan’s assets and rights related to the Alzheimer’s Immunotherapy Program (AIP), a joint collaboration with Pfizer.

Darren has a proven track record in Finance at J&J. Darren joined J&J through the acquisition of Centocor in 1999. He spent three years at Centocor prior to the acquisition and three years after, in positions of increasing responsibility and in support of a variety of functions including Commercial, R&D, and Business Development.

In 2002, Darren moved to J&J Corporate, where he spent three years in the Mergers and Acquisitions Finance group providing financial leadership on more than 100 potential acquisitions, major licensing deals, equity investments, options, structures, and divestitures across all sectors. Following his time at Corporate, Darren spent two years in the Bay Area with Scios/ALZA as Commercial and R&D Controller before joining Cordis in 2007 and Janssen AI in September 2009.

Prior to becoming CFO at Janssen AI, he was Commercial Controller for the Cordis Franchise, providing financial leadership to the US Operating Board and the Commercial Leadership Team including U.S. Selling, Marketing, Business Operations, and Global Strategic Marketing.

Darren holds a B.A. Honors Degree in Economics and Philosophy from Southampton University in England, and an MBA from Villanova University. Last year he was selected to participate in J&J’s prestigious Accelerated Enterprise Leader Program. Darren has also completed Finance and Business Development Leadership Programs at both Harvard and Wharton.

Christiana Stamoulis is a senior executive in the biopharmaceutical industry, with extensive experience in developing strategies for sustainable growth, and expertise in the execution of complex M&A deals, strategic collaborations and capital raising transactions. She brings nearly 20 years of experience in the life sciences industry as a strategic and corporate finance advisor to CEOs and Boards of Directors of global biopharmaceutical companies, a senior executive and a director of a public company board.

Ms. Stamoulis currently serves as an independent director of the Board of Hologic Inc., (Nasdaq: HOLX; Market cap: $7 billion) a leading global developer, manufacturer and supplier of diagnostic products, medical imaging systems, and surgical products and is a member of the Audit Committee and the Corporate Development Committee.

For the past 4 years, Christiana was the Senior Vice President and Head of Corporate Strategy and Business Development at Vertex Pharmaceuticals (Nasdaq: VRTX; Market cap: $22 billion) and a member of Vertex’s Executive Team. She helped develop Vertex’s corporate vision of the future and led the development of strategies and initiatives to achieve this vision. She also led the identification, evaluation and execution of key business collaborations to enable Vertex to achieve its strategic objectives and position the company for sustainable long-term growth.

Prior to joining Vertex, Ms. Stamoulis spent nearly 15 years in the investment banking and management consulting industries. She was a Managing Director at Citigroup’s Investment Banking division and led the building of the firm’s Life Sciences group. Prior to Citigroup, Ms. Stamoulis was in the Healthcare Investment Banking Group at Goldman, Sachs & Co., where she spent the majority of her investment banking career. As an investment banker, she has advised clients and has led the execution of M&A and capital raising deals with aggregate value in excess of $100 billion.

Ms. Stamoulis started her professional career as a strategy consultant at The Boston Consulting Group where she advised clients on major strategy and organizational change initiatives. She holds an MBA from the Massachusetts Institute of Technology (MIT) Sloan School of Management with a concentration in Applied Economics and Finance, as well as two Bachelor of Science degrees, in Economics and Architecture, respectively, also from MIT.

Roger M. Stein has been actively engaged in developing, implementing and writing about new approaches to applied risk modeling and financial prediction for almost 25 years. He and his teams have developed, implemented and delivered products and services that have become industry benchmarks in banking and finance.

He is currently Senior Lecturer in finance at the MIT Sloan School of Management and also holds the position of Research Affiliate at the MIT Laboratory for Financial Engineering. He is also an Affiliated Researcher at the Center for Risk Management Research, University of California, Berkeley. His current research interests are in the areas of systemic risk, credit risk, model risk and validation, biomedical funding, and the interface between data mining and financial theory.

In addition to his academic work, he has held a number of senior positions in industry. He was the Chief Analytics Officer at State Street GX, as well as Senior Managing Director of Product Strategy. Before this he was Managing Director of Research and Academic Relations globally for Moody’s Corporation and prior to this he was President of Moody’s Research Labs (MRL), a wholly owned subsidiary of Moody’s Corporation, where he led a team of researchers and engineers charged with incubating a number of innovative quantitative technologies for assessing credit and other forms of financial risk. The firm’s research spanned diverse domains including mortgage-, municipal- and retail-credit risk, microfinance, and systemic risk. Upon reaching maturity, the products and methodologies incubated by MRL were transitioned to other operating units of Moody’s Corporation for ongoing production. Stein also headed the Managed Funds group at Moody’s Investors Service for several years during which time he introduced new quantitative approaches to various aspects of the ratings process.

Earlier in his career, Dr. Stein was co-head of research at Moody’s KMV. There he led the commercial development of risk management tools (including RiskCalc™ and LossCalc™) that are in use at hundreds of financial institutions worldwide, as well as creating customized analytic services for clients. Before his work at MKMV, Stein was the Head of Research at Moody’s Risk Management Services (MRMS) where he oversaw a team of researchers focused on building products to assess various forms of corporate credit risk. At MRMS Stein and his colleagues also developed a number of methodologies for validating and testing risk model performance that have become standard approaches in industry and academia.

Dr. Stein has written over fifty professional and academic articles and serves on the editorial boards of several finance journals. He has also co-authored two full-length texts on applied analytics: Active Credit Portfolio Management in Practice (Wiley, 2009), on practical credit risk management; and Seven Methods for Transforming Corporate Data into Business Intelligence (Prentice Hall, 1997), on commercial applications of data analytics, data mining (big data) and decision systems. Stein is a frequent invited speaker at industry, academic and regulatory venues.

In addition to his professional work he the founder and president of the Consortium for Systemic Risk Analytics and a member of the Advisory Council of the Museum of Mathematics; the Board of PlaNet Finance, USA, and the Academic Advisory Board of the EC’s SYstemic Risk Tomography Project (SYRTO).

Dr. Stein holds a Ph.D. and Masters degree from the Stern School of Business, New York University, and a Bachelors degree in Mathematics and Japanese Studies from the State University of New York at Binghamton, with undergraduate minors in Russian and East Asian Studies. He has been practicing Aikido since 1980.

Vikas P. Sukhatme MD PhD is the Victor J. Aresty Professor of Medicine at Harvard Medical School, and Chief Academic Officer and Harvard Faculty Dean for Academic Programs at Beth Israel Deaconess Medical Center.

He holds a doctorate in physics from MIT and an MD from Harvard. His research contributions span numerous areas of medicine and are in both basic science and clinical arenas. His longstanding interest in cancer currently centers around tumor metabolism and tumor immunology and on “outside-of-the-box” approaches for treating advanced cancer. He has conducted studies on genes important in kidney cancer. He was part of the team that uncovered the cause of preeclampsia, a blood vessel disorder and a major cause of morbidity in pregnant women. His research has provided insights into how blood vessels leak in patients with severe infections and on how new vessels form to feed growing tumors. He has elucidated mechanisms by which statins can cause muscle damage. Finally, he is a co-founder of a not-for-profit organization, GlobalCures, whose goal is to conduct clinical trials on promising therapies for cancer not being pursued for lack of profitability.

Marty Tenenbaum, Cancer Commons, please follow link for bio.

Jake Xia, Harvard Management Company, please follow link for bio.